



PRESS RELEASE

23 April 2025 15:15:00 CEST

Senzime secures new system-wide contract with major Pacific northwest US healthcare system

Uppsala, Sweden – Senzime AB today announced that it has secured an additional system-wide contract with a US healthcare system. The contract includes an initial order of 65 next-generation TetraGraph systems for monitoring patients under neuromuscular block for use at multiple hospital locations in the Pacific Northwest region.

“We continue to secure contracts with leading hospitals in the US, and our innovative technology is gaining traction to be the new gold standard in operating rooms. The Pacific Northwest region is of strategic importance and highly ranked for its high quality and accessible healthcare. Furthermore, it’s reassuring to note that once again a leading US hospital system values our new TetraGraph system with its unique design and features that has the capabilities to help accelerate the adoption of the recent practice recommendations of patients undergoing anesthesia”, comments Philip Siberg, CEO of Senzime.

Senzime’s TetraGraph system is used by anesthesiologists in over 3,500 operating rooms in leading hospitals worldwide. Its proprietary technology meets the requirements of the recently published US and European guidelines recommending neuromuscular monitoring of all patients receiving paralytic drugs. TetraGraph helps to accurately determine the correct dose of paralytic drugs and their antagonists and determines when patients have safely recovered post-surgery.

For further information, please contact:

Philip Siberg, CEO of Senzime AB

Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

About Senzime

Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime’s TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime’s products are commercialized in over 30 countries including direct sales teams in US and Germany.

Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at senzime.com.

Attachments

Senzime secures new system-wide contract with major Pacific northwest US healthcare system